Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma

Fig. 3

Inhibition of GSK3 activity by SB216763 stabilized MAFb protein. HMCLs were treated with 5 μg/ml of CHX for serial indicated time points to inhibit de novo protein synthesis. The MAFb protein was determined by immunoblotting analysis using anti-MAFb. The membranes were striped and reblotted with Anti-β-actin (a). The half-life of MAFb protein was determined by autoradiographs analysis using Adobe Photoshop software and NIH image software (b-f). HMCLs were treated with or without a specific GSK3 inhibitor, SB216763, at a concentration of 5 μg/ml for indicated times. MAFb protein was determined by immunoblotting analysis using anti-MAFb antibody. The membranes were striped and reblotted with Anti-β-actin to indicate protein loading (a). The protein decay curve is as described in Fig. 3b (b-f)

Back to article page
\